InvAscent Writes Bigger Pharma Cheques Amid Rising Costs
Hyderabad-based PE firm InvAscent increases investment ticket sizes in pharmaceuticals to $80-100 million deals, driven by higher regulatory and manufacturing costs. The firm allocates 50% to pharma, 30% to healthcare, and 20% to allied segments.